2. Academic Validation
  3. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

  • Antimicrob Agents Chemother. 2007 Sep;51(9):3397-400. doi: 10.1128/AAC.01242-06.
Cédric Jacqueline 1,  Jocelyne Caillon,  Virginie Le Mabecque,  Anne-Françoise Miègeville,  Antoine Hamel,  Denis Bugnon,  James Yigong Ge,  Gilles Potel
Affiliations

Affiliation

  • 1 Université de Nantes, Nantes Atlantique Universités, Thérapeutiques Cliniques et Expérimentales des Infections, EA3826, UFR Médecine, Nantes, France.
PMID: 17591849 DOI: 10.1128/AAC.01242-06
Abstract

Using the rabbit endocarditis model, we compared the activity of a new broad-spectrum cephalosporin, ceftaroline, with those of linezolid and vancomycin against methicillin-resistant Staphylococcus aureus. After a 4-day treatment, ceftaroline exhibited superior bactericidal in vivo activity against resistant S. aureus strains and appeared to be the most effective drug against a heterogeneous glycopeptide-intermediate S. aureus strain.

Figures
Products